Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | ADH4 | P08319 | 1/20 | 0.42 |
| ▸ | ADH7 | P40394 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22157430 | 0.84 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL8939140 | 0.83 | ADH1B (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL22157414 | 0.82 | ADH1B (0.37) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL22157377 | 0.79 | TSHR (0.31) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL22157349 | 0.79 | ADH1B (0.35) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10909087 | 0.78 | FAAH (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11435239 | 0.77 | ADH1B (0.64) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11110933 | 0.77 | ADH1B (0.64) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL22157458 | 0.76 | TAS1R3 (0.30) | — | |
| SCHEMBL8374807 | 0.76 | ADH1B (0.47) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745002-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | ADH1B 369/4885ADH1C 570/4885ADH1A 322/4885 |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | PPARG, PPARD, GPR119 | ADH1B 599/4885ADH1C 462/4885ADH1A 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.